Comprehensive prognostic and immune analysis of sterol O-acyltransferase 1 in patients with hepatocellular carcinoma

doi:10.4254/wjh.v16.i3.439

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1069)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

HTML

746

Figures (1-7)

Sum=861

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

128

Sum=163

Mar 27, 2024 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Mar 27, 2024; 16(3): 439-451
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.439

Full Size Figure Download Figure

Figure 4 Prognostic value of sterol O-acyltransferase 1 expression in liver hepatocellular carcinoma. A: Nomograms for 1-, 3-, and 5-year overall survival in different subgroups based on sterol O-acyltransferase 1 (SOAT1) expression and other clinical characteristics in liver hepatocellular carcinoma (LIHC); B: Calibration for 1-, 3-, and 5-year overall survival in different subgroups based on SOAT1 expression and other clinical characteristics in LIHC; C: Nomograms for 1-, 3-, and 5-year disease specific survival in different subgroups based on SOAT1 expression and other clinical characteristics in LIHC; D: Calibration for 1-, 3-, and 5-year disease specific survival in different subgroups based on SOAT1 expression and other clinical characteristics in LIHC.

Citation: Gan CJ, Zheng Y, Yang B, Cao LM. Comprehensive prognostic and immune analysis of sterol O-acyltransferase 1 in patients with hepatocellular carcinoma. World J Hepatol 2024; 16(3): 439-451
URL: https://www.wjgnet.com/1948-5182/full/v16/i3/439.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i3.439